-GBA >In $93
-GBA Out 94.84 +2.96 (+3.22%)
1000 shares cost $93,000. <----------- This is why maybe the DBI.
-GBA Out 94.84 +2.96 (+3.22%)
1000 shares cost $93,000. <----------- This is why maybe the DBI.
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
You can take $6.50 now.
$97.50
My Boy he just left Van for Prom. Black suit. Why do they have to grow up
Or... In $91, out $98... and play DBI tomorrow with all that dry powder.
$7K on $23.5K w/dtbp----> 33% return.
Scrotum bank getting friskY!
Twilio initiated with an Outperform at Scotiabank 16:42 TWLO Scotiabank initiated…
Twilio initiated with an Outperform at Scotiabank 16:42 TWLO Scotiabank initiated…
Good News CHWY fans-
Chewy director Star buys $5.0M in common stock 16:44 CHWY In a regulatory filing,…
Chewy director Star buys $5.0M in common stock 16:44 CHWY In a regulatory filing,…
I don't understand this but stay away Van-
Upstart may see lower originations after CFPB action, says Wedbush » 16:29 UPST Wedbush analyst David
Upstart may see lower originations after CFPB action, says Wedbush » 16:29 UPST Wedbush analyst David
We were talking mid stream ideas and I gave you one but it wasn't this I don't think..
Goldman upgrades Magellan Midstream to Buy on inflation benefits 16:09 MMP Goldman Sachs analyst Michael Lapides upgraded Magellan Midstream Partners to Buy from Neutral with a price target of $59, up from $55, representing almost 19% total return potential. The analyst sees upside to consensus estimates, "healthy" balance sheet metrics versus peers and capital allocation potential. Magellan maintains positive exposure to inflation trends in its refined products system pricing mechanisms and continued improvements in refined products volumes, Lapides tells investors in a research note. The analyst sees an attractive entry point at current levels, noting the partnership offers a dividend yield of 8% and is a beneficiary of elevated inflation levels.
Wow this sounds strong Van ))))))))))))))
Goldman upgrades Magellan Midstream to Buy on inflation benefits 16:09 MMP Goldman Sachs analyst Michael Lapides upgraded Magellan Midstream Partners to Buy from Neutral with a price target of $59, up from $55, representing almost 19% total return potential. The analyst sees upside to consensus estimates, "healthy" balance sheet metrics versus peers and capital allocation potential. Magellan maintains positive exposure to inflation trends in its refined products system pricing mechanisms and continued improvements in refined products volumes, Lapides tells investors in a research note. The analyst sees an attractive entry point at current levels, noting the partnership offers a dividend yield of 8% and is a beneficiary of elevated inflation levels.
Wow this sounds strong Van ))))))))))))))
Consumer Financial Protection Bureau.
They must be charging too much to originate the loans.
FLYW----> $18.77
Does this stock ever go up?!!
The children Stoney!
April 27--- over 1 month ago))))))))
- Shares of SQZ Biotechnologies (NYSE:SQZ) jumped 19.1% to $3.30 in aftermarket trading on Wednesday, after the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to the company's lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of human papillomavirus (HPV) positive cancers.
- The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
- SQZ-PBMC-HPV is being evaluated as a a monotherapy and in combination with other immuno-oncology agents in a phase 1/2 clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors.
- The human papillomavirus is one of the most common viruses worldwide. According to the CDC, HPV infection plays a significant role in the formation of more than 90% of anal and cervical cancers, along with other cancers such as vaginal and penile.